Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Buys 137,100 Shares

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall bought 137,100 shares of Immunome stock in a transaction dated Wednesday, March 26th. The shares were bought at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at $5,881,105.44. This represents a 20.47 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Immunome Stock Performance

Shares of NASDAQ IMNM traded down $0.29 during midday trading on Friday, reaching $6.99. The stock had a trading volume of 1,060,189 shares, compared to its average volume of 854,933. The company's 50 day moving average price is $9.50 and its 200 day moving average price is $11.28. Immunome, Inc. has a twelve month low of $6.90 and a twelve month high of $24.87. The firm has a market cap of $607.79 million, a price-to-earnings ratio of -0.86 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Equities analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IMNM. Wedbush reiterated an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Stephens restated an "overweight" rating and set a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Guggenheim reduced their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Finally, Lifesci Capital initiated coverage on Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $25.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of Immunome during the fourth quarter worth $70,000. KLP Kapitalforvaltning AS purchased a new position in Immunome during the 4th quarter valued at about $75,000. AlphaQuest LLC increased its position in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after buying an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome in the fourth quarter valued at approximately $95,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.